- Home
- TAC vs IBRX Comparison
TAC vs IBRX Comparison
Compare TAC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- IBRX
- Stock Information
- Founded
- TAC 1909
- IBRX 2014
- Country
- TAC Canada
- IBRX United States
- Employees
- TAC N/A
- IBRX N/A
- Industry
- TAC Electric Utilities: Central
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAC Utilities
- IBRX Health Care
- Exchange
- TAC Nasdaq
- IBRX Nasdaq
- Market Cap
- TAC 2.9B
- IBRX 2.4B
- IPO Year
- TAC N/A
- IBRX N/A
- Fundamental
- Price
- TAC $10.74
- IBRX $2.58
- Analyst Decision
- TAC Buy
- IBRX Strong Buy
- Analyst Count
- TAC 2
- IBRX 5
- Target Price
- TAC $19.75
- IBRX $11.40
- AVG Volume (30 Days)
- TAC 1.8M
- IBRX 10.3M
- Earning Date
- TAC 07-31-2025
- IBRX 08-11-2025
- Dividend Yield
- TAC 1.62%
- IBRX N/A
- EPS Growth
- TAC N/A
- IBRX N/A
- EPS
- TAC 0.00
- IBRX N/A
- Revenue
- TAC $1,847,844,992.00
- IBRX $31,222,000.00
- Revenue This Year
- TAC N/A
- IBRX $567.98
- Revenue Next Year
- TAC N/A
- IBRX $160.56
- P/E Ratio
- TAC $4,674.85
- IBRX N/A
- Revenue Growth
- TAC N/A
- IBRX 10238.41
- 52 Week Low
- TAC $6.78
- IBRX $1.83
- 52 Week High
- TAC $14.64
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- TAC 56.88
- IBRX 41.03
- Support Level
- TAC $10.56
- IBRX $2.65
- Resistance Level
- TAC $10.91
- IBRX $2.82
- Average True Range (ATR)
- TAC 0.32
- IBRX 0.16
- MACD
- TAC -0.09
- IBRX -0.06
- Stochastic Oscillator
- TAC 38.33
- IBRX 3.01
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.